US8091711015 - Common Stock
SCOPUS BIOPHARMA INC
NASDAQ:SCPS (12/16/2022, 7:25:53 PM)
After market: 0.12 -0.05 (-28.66%)0.1682
-0.17 (-50.54%)
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Its pipeline also includes MRI-1867, which is a cannabinoid receptor mediating compound for the treatment of systemic sclerosis.
SCOPUS BIOPHARMA INC
420 Lexington Ave Rm 300
New York City NEW YORK
P: 12124792513.0
Employees: 9
Website: https://scopusbiopharma.com/
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for...
Here you can normally see the latest stock twits on SCPS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: